Literature DB >> 19712130

Phenotype for activated tissue macrophages in histiocytic necrotizing lymphadenitis.

Yuko Nomura1, Masanori Takeuchi, Shiro Yoshida, Yasuo Sugita, Daisuke Niino, Yoshizo Kimura, Kei Shimizu, Ryosuke Aoki, Nobuko Suefuji, Shinichi Hirose, Masahiro Kikuchi, Koichi Ohshima.   

Abstract

Macrophage polarization is divided into M1 and M2 type based on membrane receptors, cytokines, and chemokines. M1 expresses CD80, interleukin (IL)-6, IL-12, and chemokine receptor (CCR)7, while M2 expresses CD163, IL10, and chemokine ligand (CCL)22. The aim of the present study was to identify the properties of infiltrating tissue macrophages in histiocytic necrotizing lymphadenitis (HNL). Twenty patients with HNL were studied, and immunohistochemistry for CD68 (KP1), CD163, CCL22, CCR7, and CD123 was done, along with myeloperoxidase (MPO). To evaluate the phenotypes of tissue macrophages in HNL, the number of cells stained positively for CD163, CCL22, CCR7, CD123 and MPO concurrently with CD68 was counted, and the ratio was calculated for each antibody to CD68+ cells. There was a high rate of co-expression for CD163 (median, 78%) or CCL22 (80%) and a low rate for CCR7 (5%) in CD68+ cells. It is therefore conceivable that infiltration by M2 macrophages is dominant in HNL. Furthermore, some CD68+ tissue macrophages in HNL co-express MPO or CD123 (range, 5-80%; median, 23% and 40%, respectively). It is suggested that these characteristic tissue macrophages may be associated with the pathogenesis of HNL and that M2 macrophages may infiltrate to repair the lymphoid tissue injured by cytotoxic T cells in HNL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19712130     DOI: 10.1111/j.1440-1827.2009.02418.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  5 in total

1.  Activated macrophages containing tumor marker in colon carcinoma: immunohistochemical proof of a concept.

Authors:  T J E Faber; D Japink; M P G Leers; M N Sosef; M F von Meyenfeldt; M Nap
Journal:  Tumour Biol       Date:  2011-12-02

Review 2.  Co-occurrence of Kikuchi-Fujimoto's disease and Still's disease: case report and review of previously reported cases.

Authors:  Karen A Toribio; Hideko Kamino; Stephanie Hu; Miriam Pomeranz; Michael H Pillinger
Journal:  Clin Rheumatol       Date:  2014-08-08       Impact factor: 2.980

3.  Monocyte-induced recovery of inflammation-associated hepatocellular dysfunction in a biochip-based human liver model.

Authors:  Marko Gröger; Knut Rennert; Benjamin Giszas; Elisabeth Weiß; Julia Dinger; Harald Funke; Michael Kiehntopf; Frank T Peters; Amelie Lupp; Michael Bauer; Ralf A Claus; Otmar Huber; Alexander S Mosig
Journal:  Sci Rep       Date:  2016-02-23       Impact factor: 4.379

4.  Kikuchi's disease with hemophagocytic lymphohistiocytosis: A case report and literature review.

Authors:  Wei Duan; Zheng-Hui Xiao; Long-Gui Yang; Hai-Yan Luo
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

5.  Histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto disease) after laparoscopic Roux-en-Y gastric bypass for morbid obesity: a case report.

Authors:  Juan Garcia-Arnes; M Rosa Bernal-Lopez; Jose Luis Gallego-Perales; M Luz Vazquez-Camuñas; Ricardo Gomez-Huelgas
Journal:  J Med Case Rep       Date:  2012-10-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.